Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: A new diagnostic tool to evaluate the early effects of antiangiogenic treatment

European Radiology, Supplement

Volumn 17, Issue SUPPL. 6, 2007, Pages

  Lassau, Nathalie ^a   Chami, Linda ^a   Benatsou, Baya ^a   Peronneau, Pierre ^a   Roche, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antiangiogenic treatments; Dynamic contrast enhanced ultrasonography; Tumor perfusion quantification

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CONTRAST MEDIUM; ERLOTINIB; FLUORODEOXYGLUCOSE; IMATINIB; INTERFERON; IRINOTECAN; PLACEBO; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SHU 508; SONOVUE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; ECHOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; MICROVASCULATURE; ORGAN PERFUSION; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SOLID TUMOR; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CONTRAST MEDIA; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOLIPIDS; SULFUR HEXAFLUORIDE; ULTRASONOGRAPHY, DOPPLER, COLOR; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 40349113040     PISSN: 16133749     EISSN: 16133757     Source Type: Journal    
DOI: 10.1007/s10406-007-0233-6     Document Type: Article

References (23)

1. Rehman S, Jayson GC (2005) Molecular imaging of antiangiogenic agents. Oncologist 10:92-103
2. Schwartz L (2004) Conventional and novel techniques for therapeutic response assessment. Radiological Society North America (RSNA). 90th Scientific Assembly and Annual Meeting, Chicago, December 2004
3. Benjamin RS, Choi H, Macapinlac HA et al (2007) We should desist using Recist, at least in GIST. J Clin Oncol 25:1760-1764
4. Cosgrove D (2003) Angiogenesis imaging-ultrasound. Br J Radiol 76(Spec No 1):S43-S49
5. Lassau N, Koscielny S, Opolon P et al (2001) Evaluation of contrast-enhanced color Doppler ultrasound for the quantification of angiogenesis in vivo. Invest Radiol 36:50-55
6. Escudier B, Lassau N, Couanet D et al (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13:1029-1035
7. Greis C (2004) Technology overview: SonoVue (Bracco, Milan). Eur Radiol 14[Suppl 8]:P11-P15
8. Lassau N, Lamuraglia M, Vanel D et al (2005) Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: Prospective study of 49 cases. Ann Oncol 16:1054-1060
9. Lassau N, Lamuraglia M, Chami L et al (2006) Gastrointestinal stromal tumors treated with imatinib: Monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 187:1267-1273
10. Lamuraglia M, Escudier B, Chami L et al (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42:2472-2479
11. Escudier B, Lassau N, Angevin E et al (2007) Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13:1801-1809
12. Blay JY, Landi B, Bonvalot S et al (2005) Recommendations for the management of GIST patients. Bull Cancer 92:907-918
13. Choi H, Faria S, Benjamin R et al (2002) Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST) with CT and PET: A quantitative analysis (abstract 583). RSNA Scientific program 2002, Chicago, IL
14. De Giorgi U, Aliberti C, Benea G, et al (2005) Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 11:6171-6176
15. Le Cesne A, Landi B, Bonvalot S et al (2005) Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales. Hepato-Gastro 12:377-389
16. Lamuraglia M, Le Cesne A, Chami L et al (2006) Dynamic contrast-enhanced Doppler ultrasound (DCEUS) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM). J Clin Oncol (2006 ASCO Annual Meeting Proceedings, Post Meeting Edition, June 20) 24:529S
17. Le Cesne A, Landi B, Bonvalot S et al (2006) Recommendations for the management of gastro-intestinal stromal tumors. Ann Pathol 26:231-234
18. Kaelin WG (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673-682
19. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
20. McCarville MB, Streck CJ, Dickson PV et al (2006) Angiogenesis inhibitors in a murine neuroblastoma model: Quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 240:73-81
21. Kruskal JB (2006) Science to practice: Will improved assessment of response to antiangiogenic therapies be achieved with contrast-enhanced grayscale US? Radiology 240:1-2
22. Soria JC, Lazar V, Lassau N et al (2007) Sorafenib (S) and dacarbazine (D) combination in patients with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US). 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 25[Suppl 18]:151s
23. Lassau N, Chami L, Peronneau P (2007) Imaging of melanoma: Accuracy of ultrasonography before and after contrast injection for diagnostic and early evaluation of treatment. Bull Cancer 94:93-98